PharmaResearch Co., Ltd. (KOSDAQ:214450)
South Korea · Delayed Price · Currency is KRW 302,000
+5,000 (1.68%)
Apr 10, 2026, 3:30 PM KST
PharmaResearch Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 536,289 | 350,115 | 261,011 | 194,759 | 154,083 |
Other Revenue | - | - | -0 | -0 | -0 |
| 536,289 | 350,115 | 261,011 | 194,759 | 154,083 | |
Revenue Growth (YoY) | 53.17% | 34.14% | 34.02% | 26.40% | 41.69% |
Cost of Revenue | 125,072 | 98,878 | 70,753 | 53,246 | 45,750 |
Gross Profit | 411,217 | 251,237 | 190,258 | 141,513 | 108,333 |
Selling, General & Admin | 149,772 | 94,670 | 73,828 | 58,572 | 42,832 |
Research & Development | 35,858 | 21,176 | 15,030 | 8,702 | 6,738 |
Amortization of Goodwill & Intangibles | 4,294 | 3,745 | 3,521 | 3,796 | 3,592 |
Other Operating Expenses | 702.31 | 618.58 | 556.23 | 648.65 | 313.55 |
Operating Expenses | 198,891 | 125,187 | 98,001 | 75,597 | 55,844 |
Operating Income | 212,327 | 126,051 | 92,258 | 65,916 | 52,489 |
Interest Expense | -10,392 | -4,634 | -2,987 | -3,830 | -1,314 |
Interest & Investment Income | 16,232 | 10,174 | 7,403 | 5,272 | 3,726 |
Earnings From Equity Investments | -2,927 | - | - | - | - |
Currency Exchange Gain (Loss) | -907.85 | 4,955 | -379.95 | 207.69 | 155.77 |
Other Non Operating Income (Expenses) | -1,343 | -6,028 | 3,396 | -3,220 | 124.32 |
EBT Excluding Unusual Items | 212,989 | 130,517 | 99,690 | 64,346 | 55,181 |
Gain (Loss) on Sale of Investments | 5,081 | -14,238 | 4,210 | -5,023 | 1,462 |
Gain (Loss) on Sale of Assets | -162.14 | -11.92 | 36.11 | -113.69 | 229.6 |
Asset Writedown | -1,394 | - | -3,231 | -5,161 | -839.66 |
Other Unusual Items | - | -454.59 | - | - | - |
Pretax Income | 216,514 | 115,813 | 100,705 | 54,048 | 56,033 |
Income Tax Expense | 48,259 | 26,870 | 23,440 | 10,614 | 9,210 |
Earnings From Continuing Operations | 168,255 | 88,943 | 77,265 | 43,434 | 46,824 |
Minority Interest in Earnings | -3,134 | 3,100 | -713.44 | -2,857 | -134.98 |
Net Income | 165,121 | 92,043 | 76,551 | 40,577 | 46,689 |
Net Income to Common | 165,121 | 92,043 | 76,551 | 40,577 | 46,689 |
Net Income Growth | 79.40% | 20.24% | 88.66% | -13.09% | 42.45% |
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 |
Shares Outstanding (Diluted) | 11 | 10 | 11 | 10 | 10 |
Shares Change (YoY) | 7.41% | -2.50% | 5.85% | -0.76% | 5.74% |
EPS (Basic) | 15893.00 | 8941.00 | 7571.24 | 4067.47 | 4716.62 |
EPS (Diluted) | 14933.00 | 8941.00 | 7487.07 | 4067.00 | 4714.88 |
EPS Growth | 67.02% | 19.42% | 84.09% | -13.74% | 36.78% |
Free Cash Flow | 153,435 | 101,707 | 52,883 | 42,147 | 44,652 |
Free Cash Flow Per Share | 13876.17 | 9879.74 | 5008.31 | 4224.85 | 4441.83 |
Dividend Per Share | - | - | 950.000 | 660.000 | 600.000 |
Dividend Growth | - | - | 43.94% | 10.00% | 20.00% |
Gross Margin | 76.68% | 71.76% | 72.89% | 72.66% | 70.31% |
Operating Margin | 39.59% | 36.00% | 35.35% | 33.84% | 34.06% |
Profit Margin | 30.79% | 26.29% | 29.33% | 20.83% | 30.30% |
Free Cash Flow Margin | 28.61% | 29.05% | 20.26% | 21.64% | 28.98% |
EBITDA | 228,142 | 139,696 | 104,253 | 76,518 | 62,041 |
EBITDA Margin | 42.54% | 39.90% | 39.94% | 39.29% | 40.27% |
D&A For EBITDA | 15,815 | 13,645 | 11,996 | 10,602 | 9,552 |
EBIT | 212,327 | 126,051 | 92,258 | 65,916 | 52,489 |
EBIT Margin | 39.59% | 36.00% | 35.35% | 33.84% | 34.06% |
Effective Tax Rate | 22.29% | 23.20% | 23.28% | 19.64% | 16.44% |
Advertising Expenses | 53,346 | 29,642 | 22,601 | 18,381 | 9,339 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.